Prime Medicine

United States
Primghar, Iowa, United States, 02139

Company profile

Prime Medicine company profile

Prime Medicine develops gene editing therapies based on Prime Editing, a technology that enables the precise correction of genetic mutations at their source. The company focuses on treating genetic diseases by repairing DNA without making double-strand breaks, offering an alternative to traditional CRISPR approaches. Prime Editing is designed to target and correct a wide variety of mutations, allowing the development of therapeutic programs across multiple organ systems. Prime Medicine's pipeline includes investigational therapies for diseases affecting the liver, eye, blood, and central nervous system. The company integrates its proprietary delivery platforms and screening tools to enhance the specificity and durability of gene edits. Its research and development efforts aim to translate advances in genome editing into clinical applications with the potential for one-time, curative treatments.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$1M-$10M
Founded
2019-01-01, Year

Headquarters

Postal code
02139
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
7
Total equity funding
$558.2M
Last funding
Post IPO Equity / $5M / 2025-08-01
Last equity funding
Post IPO Equity / $5M
Investors
14
Lead investors
5
Founders
2
Articles
169
Exited on
2022-10-20

Founders and investors

Founders

Andrew AnzaloneDavid R. Liu

Lead investors

ARCH Venture PartnersBristol-Myers SquibbCystic Fibrosis FoundationF-PrimeGoogle Ventures

Investors

ARCH Venture PartnersCormorant Asset ManagementF-PrimeRedmile GroupSamsara BioCapital